Transcription factor NRF2 and the expression of the Hippo pathway effector TAZ in bladder tumorigenesis are significantly correlated Authors: Mohammad Vahabirad, Hadi Ghasemi, Atefeh Pegah, Zahra Goli, Heidar Tavilani Published: 2025 ABSTRACT Bladder cancer ranks as the 11th most frequent form of cancer and is the most common malignancy of urinary tract cells. A major contributor to bladder cancer development is oxidative stress. The nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of the transcriptional coactivator with PDZ-binding motif (TAZ) and is found to regulate oxidative stress in cancer cells. This study aimed to investigate the relationship between oxidative stress and the NRF2/TAZ pathway in bladder cancer. In this study, a total of 35 bladder cancer patients and 35 healthy subjects were recruited. The expression of NRF2 and TAZ genes was evaluated using real-time PCR. Total Oxidant Status (TOS) and total antioxidant capacity (TAC) of the samples were measured. Our findings revealed a higher expression of NRF2 (p < 0.001) and TAZ (p < 0.001) mRNA in cancerous tissue as compared to healthy subjects. We also found that there is a positive correlation between tumor grading and NRF2 (r = 0.522, p = 0.001) as well as TAZ (r = 0.462, p = 0.02) genes mRNA expression. Also, our results revealed that there is a significant correlation between TAZ and NRF2 genes mRNA expression in bladder cancer patients. Furthermore TAC level was considerably lower in bladder cancer patients (p < 0.01), while the TOS level was significantly higher compared to the control group(p < 0.05). Finally, our findings suggested that NRF2 and TAZ, as transcriptional factors, are associated with higher grades of bladder cancer as well as oxidative stress in patients with bladder cancer.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-025-04225-0. Introduction Cancers are a category of diseases which are characterized by the uncontrolled growth of cells and the invasion and spread of tumor cells from the site of origin to other parts of the body. They are the leading cause of death in industrialized countries, and rank as the second leading cause of death [1]. Urothelial cell carcinoma, commonly called bladder cancer, is the most common malignant tumor affecting cells within the urinary system. According to available data from 2015, the United States reported 74,000 cases of bladder cancer, with an estimated mortality rate of around 22% [2]. Bladder cancer is usually classified into two main types: muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). Based on the bladder cancer grading system, about 70% of bladder cance cases are classified as low-grade, non-invasive, and superficial papillary tumors. High-grade bladder cancer is marked by the development of invasive tumors, which occur in roughly 30% of subjects with bladder cancer [3, 4]. It has been shown that the oxidative stress may play critical role in development of various diseases, including bladder cancer [5]. In this regard, reactive oxygen species (ROS) have the potential to activate NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), leading to the production of proinflammatory cytokines. This cascade increases the inflammatory response and subsequently promotes the overproduction of ROS [6]. Additionally, ROS can activate the ROS/MAPK and ROS/Keap1-NRF2 signaling pathways, which are involved in bladder cancer development through cancer cell proliferation, migration, and invasion [7]. Sudden increase in ROS production or impairment of the antioxidant defense system can disrupt neutralizing or attenuating the oxidative damage, leading to oxidative stress. Elevated cytosolic ROS levels hinder the inhibition of NRF2 transcription factor ubiquitination by Kelch-like ECH-associated protein 1 (KEAP-1) proteins, resulting in NRF2 accumulation. NRF2 then translocates into the nucleus, where it forms a heterodimer with MAF proteins and acts as a transcription factor [8]. This heterodimer binds to the antioxidant response element (ARE) sequence in DNA, which is found in the regulatory region of over 200 genes including genes involving in tumor growth, metastasis, and resistance to chemotherapy drugs in tumors [9]. The NRF2 gene is highly expressed in embryonic, pluripotent, and malignant cells. For instance, it has been demonstrated that there is an augmented level of NRF2 activity in glioblastoma. NRF2 can bind to the Yes-associated protein (YAP) and PDZ-binding motif (TAZ) gene promoters and can increase the expression of these proteins. YAP and TAZ, as downstream effectors of the Hippo signaling pathway [10], may promote organ growth, cell differentiation, and invasion of cancer cells through these proteins. Increased expression of TAZ protein has also been observed in a variety of human tumors [11]. The association between an increased NRF2 transcription factor and increased expression of YAP/TAZ proteins have been demonstrated in bladder cancer. Moreover, previous studies have reported that genetic alterations in the axis of NRF2-KEAP1 can lead to constitutive activation of antioxidant responses, thereby promoting cancer cell survival and therapy resistance [12]. Recent evidence has also revealed a bidirectional regulatory relationship between NRF2 and TAZ, where NRF2 induces TAZ expression, and TAZ in turn modulates NRF2-mediated antioxidant signaling and autophagy-lysosomal function [13]. These findings suggest that the interplay between NRF2 and TAZ may contribute to redox imbalance and tumor progression, warranting investigation of their coordinated role in bladder cancer.Given the emerging evidence of NRF2 and Hippo pathway crosstalk in various malignancies, we hypothesized that NRF2 and TAZ expression levels are positively correlated in bladder cancer and associated with oxidative stress status. This study aimed to evaluate the mRNA expression of NRF2 and TAZ and to assess their relationship with systemic oxidative stress markers across different tumor grades. Materials and methods Patients and study design This study was reviewed and approved by the Ethics Committee of Hamadan University of Medical Sciences (IR.UMSHA.REC.1400.263). All procedures were conducted in accordance with the ethical standards of the responsible institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments. Written informed consent was obtained from all participants before their inclusion. A total of 35 bladder cancer patients were recruited consecutively from April 2019 to January 2020 from Shahid Beheshti Hospital of Hamadan, Iran. Following the cystoscopy procedure, patients with cell abnormalities were selected to undergo Transurethral resection (TUR) of bladder tumors. The sample size (n = 35 per group) was determined based on previous studies reporting similar sample sizes sufficient to detect moderate correlations with a power >0.8 [14]. Cancerous tissue were collected from 35 patients and divided into two sections. A qualified pathologist used conventional techniques to diagnose malignant tissues and assign a grading system to them. Tumor grading was performed by an experienced pathologist according to the 2016 WHO/ISUP classification of urothelial carcinomas. Adjacent normal tissue (≥ 3 cm from tumor margin) was collected from the same bladder during TUR surgery and confirmed histologically as non-tumorousby a pathologist. For RNA extraction, cDNA synthesis, and gene expression analysis, one portion was frozen in liquid nitrogen, while the other was fixed in %10 formalin for pathological examinations. Blood samples were taken from patients as well as healthy people of the same age and gender. Serum was isolated from whole blood samples and stored at −70 °C for biochemical assay. Demographic characteristics, such as age, sex, site of primary neoplasm, date of diagnosis, family history of cancer, and other diseases, were recorded. The study excluded cases with acute or chronic disorders, other malignancies, and a history of chemotherapy and radiotherapy. RNA extraction and real‑time PCR Total RNA was extracted using the RNX-Plus solution (Cinnagen, Tehran, Iran) according to the manufacturer’s protocol. RNA quantity and purity were assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific, USA), and integrity was confirmed by 1% agarose gel electrophoresis. Complementary DNA (cDNA) was synthesized using the RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA) following the manufacturer’s instructions. Quantitative real-time PCR (qPCR) was performed using SYBR Green Master Mix (Amplicon, Denmark) on a LightCycler 96 instrument (Roche Life Science Deutschland GmbH, Sandhofer, Germany). Specific primers for NRF2, TAZ, and β-actin were designed using GenBank sequences (https://www.ncbi.nlm.nih.gov) and synthesized by Takapou Zist Company (Tehran, Iran). Primer sequences, predicted amplicon sizes, and PCR cycling conditions are presented in Table 1. Table 1Primer set sequences and expected amplicon sizeGenePrimer sequence (5′−3′)Amplicon SizePCR cycling conditions NRF2 F: ATAGCTGAGCCCAGTATCR: CATGCACGTGAGTGCTCT38895 °C for 15 min; 40 cycles of 95 °C for 25 s, 50 °C for 30 s, and 72 °C for 30 s TAZ F: GACCCCAGACATGAGATCCAR: CCTGCGTTTTCTCCTGTATCC18095 °C for 15 min; 40 cycles of 95 °C for 25 s, 55 °C for 30 s, and 72 °C for 30 s β-actin F: ACAGAGCCTCGCCTTTGCR: ATCACGCCCTGGTGCCT18695 °C for 15 min; 40 cycles of 95 °C for 25 s, 62 °C for 30 s, and 72 °C for 30 s Table 1Primer set sequences and expected amplicon sizeGenePrimer sequence (5′−3′)Amplicon SizePCR cycling conditions NRF2 F: ATAGCTGAGCCCAGTATCR: CATGCACGTGAGTGCTCT38895 °C for 15 min; 40 cycles of 95 °C for 25 s, 50 °C for 30 s, and 72 °C for 30 s TAZ F: GACCCCAGACATGAGATCCAR: CCTGCGTTTTCTCCTGTATCC18095 °C for 15 min; 40 cycles of 95 °C for 25 s, 55 °C for 30 s, and 72 °C for 30 s β-actin F: ACAGAGCCTCGCCTTTGCR: ATCACGCCCTGGTGCCT18695 °C for 15 min; 40 cycles of 95 °C for 25 s, 62 °C for 30 s, and 72 °C for 30 s Primer set sequences and expected amplicon size F: ATAGCTGAGCCCAGTATC R: CATGCACGTGAGTGCTCT F: GACCCCAGACATGAGATCCA R: CCTGCGTTTTCTCCTGTATCC F: ACAGAGCCTCGCCTTTGC R: ATCACGCCCTGGTGCCT Primer specificity was verified by melting-curve analysis showing a single sharp peak for each amplicon and by electrophoretic visualization of single bands of expected sizes. Amplification efficiency was evaluated using a three-point serial dilution standard curve. The slopes, efficiencies, and correlation coefficients (R²) for each primer pair were as follows: NRF2: slope = −3.38, efficiency = 97%, R² = 1.00; TAZ: slope = −3.40, efficiency = 96%, R² = 0.99; and β-actin: slope = −3.59, efficiency = 90%, R² = 1.00, confirming reliable amplification performance within the accepted efficiency range (90–110%). Relative mRNA expression levels were calculated using the 2^-ΔΔCt method, with β-actin serving as the internal reference gene for normalization. Primer specificity and amplification efficiency data are provided in Supplementary Figures S1 and S2. Measurement of serum total oxidant status (TOS) Serum level of TOS was determined using the FOX (ferrous oxidation–xylenol orange) assay, as previously described [23]. In this method, oxidizing agents present in the sample convert ferrous (Fe²⁺) ions to ferric (Fe³⁺) ions, which subsequently form a purple complex with xylenol orange in an acidic medium. The absorbance of this complex was measured spectrophotometrically at 560 ± 10 nm. Hydrogen peroxide (H₂O₂) was used to generate a standard calibration curve (r² = 0.998), and results were expressed as micromoles of H₂O₂ equivalents per milligram of protein. All measurements were performed in duplicate. Intra-assay precision, determined from repeated measurements of pooled serum, was less than 5%. Measurement of serum total antioxidant capacity (TAC) serum levels of TAC was assessed using the FRAP (ferric reducing ability of plasma) method. This assay measures the ability of plasma antioxidants to reduce ferric (Fe³⁺) to ferrous (Fe²⁺) ions in the presence of 2,4,6-tripyridyl-s-triazine (TPTZ) under acidic conditions, forming an Fe²⁺-TPTZ complex that absorbs at 593 nm. A calibration curve was prepared using freshly prepared FeSO₄ solutions (r² = 0.997). All assays were conducted in duplicate, and intra-assay coefficient of variation was below 6%. To ensure reproducibility and accuracy, all samples, blanks, and standards were processed under identical conditions. Data analysis The statistical analysis was performed by SPSS software version 16 (SPSS Inc., Chicago, IL). Data distribution was assessed using the Shapiro-Wilk test. Non-normally distributed variables were log-transformed before analysis to meet parametric test assumptions. Mann-Whitney and Student T-tests were used to evaluate the proportions of parametric and non-parametric variable outcomes. In this study, a p-value of less than 0.05 was statistically considered significant. Correlation analyses were performed using Pearson’s or Spearman’s test, as appropriate. Correlation strength was interpreted according to Cohen’s criteria: r < 0.3 as weak, 0.3–0.6 as moderate, and > 0.6 as strong. Results Patient demographics A total of 35 bladder cancer patients (71.4% male, 28.6% female) had a mean age of 62.3 ± 9.2 years, which was similar to the healthy controls (mean age 61.5 ± 8.9 years). There was no significant difference in age between the two groups (p = 0.701). In terms of histologic grade, 37.1% of patients were classified as Grade I, 65.7% as Grade II, and 2.8% as Grade III. No tumor grading was available for the healthy controls. The sex distribution differed slightly, with a higher proportion of males in the cancer group (71.4%) compared to controls (57.1%), though this difference was not statistically significant (p = 0.159) (Table 2). Table 2Demographic and clinical characteristics of bladder cancer patients and healthy controlsCharacteristicBladder cancer patients (n = 35)Healthy controls (n = 35)Age (mean ± SD)62.3 ± 9.261.5 ± 8.9 Sex Male25 (71.4%)20 (57.1%)Female10 (28.6%)15 (42.9%) Histologic grade Grade I16 (37.1%)N/AGrade II23 (65.7%)N/AGrade III1 (2.8%)N/A Table 2Demographic and clinical characteristics of bladder cancer patients and healthy controlsCharacteristicBladder cancer patients (n = 35)Healthy controls (n = 35)Age (mean ± SD)62.3 ± 9.261.5 ± 8.9 Sex Male25 (71.4%)20 (57.1%)Female10 (28.6%)15 (42.9%) Histologic grade Grade I16 (37.1%)N/AGrade II23 (65.7%)N/AGrade III1 (2.8%)N/A Demographic and clinical characteristics of bladder cancer patients and healthy controls NRF2 mRNA expression is correlated with bladder cancer grade The expression level of the NRF2 gene was markedly higher in cancerous tissues (4.72 ± 3.41) compared with adjacent non-cancerous tissues (1.00 ± 0.00; p < 0.001). The mean fold change was approximately 4.7 (Table 3). Additionally, NRF2 expression showed a significant positive correlation with tumor histopathological grade (r = 0.522, p = 0.001; 95% CI: 0.29–0.70) (Fig. 1). Fig. 1NRF2 Gene Expression and its Correlation with Tumor Grade in Bladder Cancer. a NRF2 gene expression was significantly higher in bladder cancer tissues compared to adjacent non-cancerous tissues (p < 0.001). Data are presented as mean ± SEM (Cancerous tissue: 4.72 ± 3.41; Normal tissue: 1.00 ± 0.00). b NRF2 expression showed a significant positive correlation with bladder cancer histopathological grade (r = 0.522, p = 0.001; 95% CI: 0.29–0.70). Pearson’s correlation coefficient and p-value are indicated NRF2 Gene Expression and its Correlation with Tumor Grade in Bladder Cancer. a NRF2 gene expression was significantly higher in bladder cancer tissues compared to adjacent non-cancerous tissues (p < 0.001). Data are presented as mean ± SEM (Cancerous tissue: 4.72 ± 3.41; Normal tissue: 1.00 ± 0.00). b NRF2 expression showed a significant positive correlation with bladder cancer histopathological grade (r = 0.522, p = 0.001; 95% CI: 0.29–0.70). Pearson’s correlation coefficient and p-value are indicated TAZ mRNA expression in cancerous and adjacent healthy tissues Further experiments showed that TAZ mRNA expression was significantly higher in malignant tissues (3.64 ± 2.15) compared to adjacent normal tissues (1.00 ± 0.00; p < 0.001), corresponding to a 3.6-fold increase (Table 3). We also found that TAZ expression was positively correlated with tumor grade (r = 0.462, p = 0.02; 95% CI: 0.15–0.73) (Fig. 2). Fig. 2TAZ Gene Expression and its Correlation with Tumor Grade in Bladder Cancer. a TAZ gene expression was significantly higher in bladder cancer tissues compared to adjacent non-cancerous tissues (p < 0.001). Data are presented as mean ± SEM (Cancerous tissue: 3.64 ± 2.15; Normal tissue: 1.00 ± 0.00). b TAZ expression was positively correlated with the histopathological grade of bladder cancer (r = 0.462, p = 0.02; 95% CI: 0.15–0.73). Pearson’s correlation coefficient and p-value are indicated TAZ Gene Expression and its Correlation with Tumor Grade in Bladder Cancer. a TAZ gene expression was significantly higher in bladder cancer tissues compared to adjacent non-cancerous tissues (p < 0.001). Data are presented as mean ± SEM (Cancerous tissue: 3.64 ± 2.15; Normal tissue: 1.00 ± 0.00). b TAZ expression was positively correlated with the histopathological grade of bladder cancer (r = 0.462, p = 0.02; 95% CI: 0.15–0.73). Pearson’s correlation coefficient and p-value are indicated NRF2 mRNA expression increases TAZ expression in bladder cancer NRF2 and TAZ mRNA levels were significantly correlated across samples (r = 0.575, p < 0.001; 95% CI: 0.32–0.81), suggesting that upregulation of NRF2 may be associated with enhanced TAZ expression in bladder cancer tissues (Fig. 3; Table 3). Fig. 3Correlation Between NRF2 and TAZ mRNA Expression in Bladder Cancer. TAZ mRNA expression was significantly correlated with NRF2 mRNA expression (r = 0.575, p < 0.001; 95% CI: 0.32–0.81). Pearson’s correlation coefficient and p-value are indicated Correlation Between NRF2 and TAZ mRNA Expression in Bladder Cancer. TAZ mRNA expression was significantly correlated with NRF2 mRNA expression (r = 0.575, p < 0.001; 95% CI: 0.32–0.81). Pearson’s correlation coefficient and p-value are indicated Oxidative stress parameters Our findings revealed that serum levels of TAC were significantly lower in patients with bladder cancer (1.93 ± 0.18 µM/mg protein) compared with healthy control group (3.67 ± 0.84 µM/mg protein; p < 0.01). Conversely, TOS levels were higher in the serum of patients with bladder cancer (37.09 ± 8.75 µM/mg protein) than in healthy control group (26.8 ± 4.62 µM/mg protein; p < 0.05) (Fig. 4; Table 3). Fig. 4Serum Oxidative Stress Parameters in Bladder Cancer Patients and Healthy Controls. a Serum levels of Total Oxidant Status (TOS) were significantly higher in bladder cancer patients compared to healthy controls (p < 0.05). Data are presented as mean ± SEM (Cancerous group: 37.09 ± 8.75 µM/mg protein; Control group: 26.8 ± 4.62 µM/mg protein). b Serum levels of Total Antioxidant Capacity (TAC) were significantly lower in bladder cancer patients compared to healthy controls (p < 0.01). Data are presented as mean ± SEM (Cancerous group: 1.93 ± 0.18 µM/mg protein; Control group: 3.67 ± 0.84 µM/mg protein) Serum Oxidative Stress Parameters in Bladder Cancer Patients and Healthy Controls. a Serum levels of Total Oxidant Status (TOS) were significantly higher in bladder cancer patients compared to healthy controls (p < 0.05). Data are presented as mean ± SEM (Cancerous group: 37.09 ± 8.75 µM/mg protein; Control group: 26.8 ± 4.62 µM/mg protein). b Serum levels of Total Antioxidant Capacity (TAC) were significantly lower in bladder cancer patients compared to healthy controls (p < 0.01). Data are presented as mean ± SEM (Cancerous group: 1.93 ± 0.18 µM/mg protein; Control group: 3.67 ± 0.84 µM/mg protein) Table 3Summary of quantitative results for NRF2, TAZ, and oxidative stress parameters in bladder cancer and adjacent normal tissuesParameterCancerous tissue (Mean ± SD)Adjacent normal tissue (Mean ± SD)Fold Changep-valueCorrelation (r)95% CINRF2 mRNA4.72 ± 3.411.00 ± 0.004.7< 0.0010.5220.29–0.70TAZ mRNA3.64 ± 2.151.00 ± 0.003.6< 0.0010.4620.15–0.73TAZ-NRF2 correlation---< 0.0010.5750.32–0.81TAC (µM/mg protein)1.93 ± 0.183.67 ± 0.84-< 0.01--TOS (µM/mg protein)37.09 ± 8.7526.8 ± 4.62-< 0.05--Data are expressed as mean ± standard deviation (SD)Fold change was calculated relative to adjacent non-cancerous tissue (normalized to 1.00)Correlation coefficients (r) represent Pearson’s correlation between the indicated variablesCI: confidence interval; TAC: total antioxidant capacity; TOS: total oxidant status Table 3Summary of quantitative results for NRF2, TAZ, and oxidative stress parameters in bladder cancer and adjacent normal tissuesParameterCancerous tissue (Mean ± SD)Adjacent normal tissue (Mean ± SD)Fold Changep-valueCorrelation (r)95% CINRF2 mRNA4.72 ± 3.411.00 ± 0.004.7< 0.0010.5220.29–0.70TAZ mRNA3.64 ± 2.151.00 ± 0.003.6< 0.0010.4620.15–0.73TAZ-NRF2 correlation---< 0.0010.5750.32–0.81TAC (µM/mg protein)1.93 ± 0.183.67 ± 0.84-< 0.01--TOS (µM/mg protein)37.09 ± 8.7526.8 ± 4.62-< 0.05--Data are expressed as mean ± standard deviation (SD)Fold change was calculated relative to adjacent non-cancerous tissue (normalized to 1.00)Correlation coefficients (r) represent Pearson’s correlation between the indicated variablesCI: confidence interval; TAC: total antioxidant capacity; TOS: total oxidant status Summary of quantitative results for NRF2, TAZ, and oxidative stress parameters in bladder cancer and adjacent normal tissues Data are expressed as mean ± standard deviation (SD) Fold change was calculated relative to adjacent non-cancerous tissue (normalized to 1.00) Correlation coefficients (r) represent Pearson’s correlation between the indicated variables CI: confidence interval; TAC: total antioxidant capacity; TOS: total oxidant status Discussion Bladder cancer remains a major global health challenge, with approximately 570,000 new cases and 210,000 deaths reported in 2020, and its incidence continues to rise worldwide [15, 16]. Understanding the molecular networks that drive its initiation and progression is therefore critical. In this study, we observed significantly elevated expression of NRF2 and TAZ mRNA in bladder cancer tissues compared with adjacent normal tissues, and both were positively correlated with tumor histopathological grade. These findings suggest that dysregulation of redox-responsive transcriptional mechanisms and Hippo pathway effectors may contribute to bladder tumor progression. The transcription factor NRF2 is known as a master regulator of antioxidant and cytoprotective responses. Under physiological conditions, NRF2 is bound to KEAP1 in the cytoplasm, which facilitates its ubiquitination and degradation. Elevated ROS and Oxidative or electrophilic stress disrupts this interaction, resulting in accumulation of NRF2 in the nucleus, dimerizing with small Maf proteins, to activate antioxidant response element (ARE)-driven genes [8, 17]. Consistent with our results, elevated NRF2 expression has been documented in multiple cancers [18], where it supports cell survival, proliferation, and chemoresistance [7, 19]. Accordingly, overexpression of NRF2 and KEAP1 in patient samples and cell lines has been linked to cisplatin resistance and poor prognosis in bladder cancer patients [20]. The significant upregulation of NRF2 in our study, as well as its correlation with tumor histological grade, further supports the involvement of NRF2 signaling in bladder carcinogenesis and progression. In this regard, recent studies have demonstrated that NRF2 signaling can contribute to the activation of several signaling cascades, including the Hippo pathway [21]. The Hippo pathway core components TAZ and YAP serve as transcriptional co-activators that modulate cell growth, proliferation, and tissue homeostasis [10, 22]. Recent studies have reported that YAP/TAZ overexpression may result in chemoresistance and are interesting therapeutic targets in cancer treatment research [23]. Additionally, aberrant TAZ/YAP activation has been reported in several solid tumors, including bladder cancer, and is associated with metastasis, epithelial-mesenchymal transition (EMT), and therapy resistance [24, 25]. Our findings of increased TAZ mRNA expression and its correlation with tumor histological grade align with previous immunohistochemical studies showing enhanced nuclear localization of TAZ in high-grade urothelial carcinoma [1, 26, 27]. Our observation of a positive correlation between NRF2 and TAZ mRNA expression in bladder cancer tissues is in line with recent evidence supporting functional crosstalk between these two molecules. Kim et al. demonstrated that TAZ directly interacts with NRF2 and modulates its transcriptional activity, while dysregulated NRF2 signaling in the absence of TAZ leads to oxidative stress and lysosomal dysfunction [13]. Moreover, constitutive activation of NRF2, often due to mutations in its negative regulator KEAP1 [12], has been implicated in enhancing redox adaptation and may indirectly influence Hippo-TAZ signaling. This supports the view the the interconnected roles of NRF2 and TAZ in oxidative stress regulation and bladder cancer progression and aggressiveness. Interestingly, we found a significant positive correlation between NRF2 and TAZ mRNA expression, which is consistent with growing evidence of functional crosstalk between the NRF2 and Hippo pathways. For instance, several studies have reported that YAP/TAZ may modulate NRF2 transcriptional activity via TEAD-FOXM1 signaling, while NRF2 can, in turn, influence YAP/TAZ activity under oxidative stress conditions and it has been shown that NRF2 can modulate TAZ expression and activity, thereby promoting oncogenic phenotypes such as proliferation and drug resistance. Based on our data, we propose that oxidative stress serves as a common upstream signal driving parallel activation of NRF2 and TAZ, collectively supporting tumor progression in bladder cancer [28]. However, given the correlative nature of our study, we cannot infer direct causality or regulatory direction between these two factors. Our results therefore indicate a possible association or co-regulation of NRF2 and TAZ in bladder cancer, which should be further explored through mechanistic assays, such as protein-level validation and pathway perturbation experiments. On the other hand, the oxidative damage caused by oxidative stress is a well-recognized driver of tumorigenesis and progression in various cancers, including bladder cancer. In this context, elevated oxidative enzymes, including xanthine oxidase, nitric oxide synthase, and prolidase, as well as lipid peroxidation products, have been observed alongside attenuated antioxidant defenses such as glutathione, superoxide dismutase, and catalase activity in patients with bladder carcinoma [29, 30]. Dogan et al. have demonstrated that of oxidative stress in bladder cancer patients may be indirectly related to the elevated levels of NRF2 and KEAP-1 in bladder cancer patients [31]. Consistent with this literature, our findings demonstrated significantly lower total antioxidant capacity and higher total oxidant status in bladder cancer patients than in healthy controls. Although serum markers may not fully reflect redox alterations within the tumor microenvironment, they provide valuable insight into the systemic oxidative imbalance accompanying malignancy. The elevated systemic oxidative burden observed here may contribute to the upregulation of NRF2 and TAZ as compensatory or adaptive responses. Integrating our findings, we propose that the NRF2-TAZ relationship may represent a redox-responsive signaling axis contributing to bladder cancer progression. Oxidative stress might simultaneously activate NRF2-dependent transcriptional programs and enhance TAZ expression or nuclear localization, thereby promoting proliferation and survival pathways. This hypothesis is consistent with prior studies demonstrating that disruption of either NRF2 or YAP/TAZ activity suppresses cancer cell proliferation, invasion, and resistance to therapy [28, 32]. Nonetheless, the absence of protein-level validation and functional assays limits definitive conclusions about mechanistic links. Limitations This study has several limitations that should be acknowledged. First, the relatively small cohort size (n = 35) may restrict the statistical power and limit the generalizability of the findings. Although several correlations reached statistical significance, these observations should be interpreted as exploratory, and validation in larger, multicenter cohorts with broader clinical and molecular diversity is needed. Second, the study assessed NRF2 and TAZ only at the mRNA level. Without complementary protein-level analyses such as immunohistochemistry or Western blotting, the extent to which transcript upregulation corresponds to altered protein expression, activation state, or subcellular localization remains uncertain. This is particularly important for TAZ, whose oncogenic activity is highly dependent on context-specific nuclear localization. Third, oxidative stress was evaluated using serum-based measurements, which may not fully reflect the redox conditions within the tumor microenvironment. Tissue-specific oxidative stress markers or redox-responsive proteins would provide a more biologically integrated assessment. Despite these limitations, the study offers preliminary evidence supporting the involvement of the NRF2-TAZ axis in bladder cancer. Future research with larger sample sizes, direct protein quantification, and mechanistic studies is needed to validate these findings and further elucidate how oxidative stress may contribute to Hippo pathway dysregulation in bladder tumor progression. Conclusion In conclusion, our findings indicate that NRF2 and TAZ expression levels are elevated in bladder cancer tissues and positively associated with tumor grade. The observed correlation between NRF2 and TAZ suggests a potential regulatory interaction contributing to tumor progression. These results highlight the involvement of oxidative stress pathways in bladder cancer through NRF2-related mechanisms. Further studies with larger cohorts and functional assays are warranted to clarify the mechanistic link and therapeutic relevance of the NRF2-TAZ axis. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.